

10/505240

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 September 2003 (25.09.2003)

PCT

(10) International Publication Number
WO 03/077785 A1

(51) International Patent Classification⁷: **A61B 19/00, A61M 25/00**

(74) Agents: **TOMBLINIG, Adrian, George et al.; Withers & Rogers, Goldings House, 2 Hays Lane, London, SE1 2HW (GB).**

(21) International Application Number: **PCT/GB03/01030**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: **11 March 2003 (11.03.2003)**

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

(25) Filing Language: **English**

(26) Publication Language: **English**


(30) Priority Data:
0205772.7 12 March 2002 (12.03.2002) GB

(71) Applicant and

(72) Inventor: **GILL, Steven, Streatfield [GB/GB]; North Bristol NHS Trust, Frenchay Hospital, Frenchay Park Road, Bristol BS16 1LE (GB).**

[Continued on next page]

(54) Title: CATHETER AND GUIDE TUBE FOR INTRACEREBRAL APPLICATION



(57) Abstract: A catheter for use in neurosurgery, and a method of positioning neurosurgical apparatus. The catheter has a fine tube arranged for insertion into the brain parenchyma of a patient with an external diameter of not more than 1.0 mm. The catheter and method may be used in stereotactically targeting treatment of abnormalities of brain function, and for the infusion of therapeutic agents directly into the brain parenchyma. This is advantageous when a therapeutic agent would have widespread unwanted effects which could be avoided by confining the delivery to the malfunctioning or damaged brain tissue.

WO 03/077785 A1